Tomasz Huzarski
A5026033317- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- DNA Repair Mechanisms
- Nutrition, Genetics, and Disease
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Trace Elements in Health
- Genetic Associations and Epidemiology
- Breast Cancer Treatment Studies
- CRISPR and Genetic Engineering
- Selenium in Biological Systems
- Genomic variations and chromosomal abnormalities
- Cancer Risks and Factors
- Heavy Metal Exposure and Toxicity
- Cancer-related Molecular Pathways
- Male Breast Health Studies
- Genetics, Bioinformatics, and Biomedical Research
- Multiple and Secondary Primary Cancers
- Estrogen and related hormone effects
- Epigenetics and DNA Methylation
- Colorectal Cancer Screening and Detection
- Prenatal Screening and Diagnostics
- Advanced Breast Cancer Therapies
- Reproductive Biology and Fertility
Pomeranian Medical University
2016-2025
International Hereditary Cancer Center
2016-2025
University of Zielona Góra
2019-2025
Read-Gene (Poland)
2012-2024
Medical University of Lublin
2023
Addenbrooke's Hospital
2015
Manchester Academic Health Science Centre
2015
University College London
2015
Princess Margaret Cancer Centre
2014
American Cancer Society
2012
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
The purposes of this study were to estimate the reduction in risk ovarian, fallopian tube, or peritoneal cancer women with a BRCA1 BRCA2 mutation after oophorectomy, by age oophorectomy; impact prophylactic oophorectomy on all-cause mortality; and 5-year survival associated clinically detected occult, cancers diagnosed cohort.Women identified from an international registry; 5,783 completed baseline questionnaire ≥ one follow-up questionnaires. Women observed until either diagnosis cancer,...
To estimate the rate of pathologic complete response (pCR) to neoadjuvant chemotherapy in BRCA1 mutation carriers according regimen.From a registry 6,903 patients, we identified 102 women who carried founder and had been treated for breast cancer with chemotherapy. Pathologic was evaluated using standard criteria.Twenty-four (24%) experienced pCR. The varied widely treatment: pCR observed one (7%) 14 cyclophosphamide, methotrexate, fluorouracil (CMF); two (8%) 25 doxorubicin docetaxel (AT);...
Ten patients with breast cancer and a susceptibility gene 1 (BRCA1) mutation, who presented stages I to III between December 2006 2007, were treated four cycles of neoadjuvant cisplatin, followed by mastectomy conventional chemotherapy.The excised tissue lymph nodes examined for the presence residual disease.Pathologic complete response was observed in nine (90%).Platinum-based chemotherapy appears be effective high proportion BRCA1-associated cancers. Clinical trials are now warranted...
The aim of this study was to estimate the contribution deleterious mutations in RAD51B, RAD51C, and RAD51D genes invasive epithelial ovarian cancer (EOC) population a screening trial individuals at high risk cancer.
To estimate the risk of breast cancer in a woman who has CHEK2 mutation depending on her family history cancer.Seven thousand four hundred ninety-four BRCA1 mutation-negative patients with and 4,346 control women were genotyped for founder mutations (del5395, IVS2+1G>A, 1100delC, I157T).A truncating (IVS2+1G>A, or del5395) was present 227 (3.0%) 37 female controls (0.8%; odds ratio [OR], 3.6; 95% CI, 2.6 to 5.1). The OR higher first- second-degree relative (OR, 5.0; 3.3 7.6) than no 3.3; 2.3...
Background: Whether oophorectomy reduces breast cancer risk among BRCA mutation carriers is a matter of debate. We undertook prospective analysis bilateral and in carriers. Methods: Subjects had no history cancer, both breasts intact, information on status (n = 3722). Women were followed until diagnosis, prophylactic mastectomy, or death. A Cox regression model was used to estimate the hazard ratios (HRs) 95% confidence intervals (CIs) associated with (coded as time-dependent variable). All...
Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face high lifetime risk of breast cancer. Surveillance MRI effective downstaging cancers, but association mortality has not been well defined.
Abstract Introduction The purpose of this investigation was to evaluate the efficacy cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. Methods In a phase II, open-label study, 20 patients cancer who carried were treated 75 mg/m 2 intravenously every 3 weeks as part 21-day cycle for 6 cycles. Restaging studies assess response performed after cycles and 6, three months thereafter. Results Between July 2007 January 2009, enrolled. Baseline characteristics follows:...
Abstract Three mutations in BRCA1 (5382insC, C61G and 4153delA) are common Poland account for the majority of identified to date Polish breast breast–ovarian cancer families. It is not known, however, what extent these 3 founder all BRCA distributed throughout country. This question has important implications health policy design epidemiologic studies. To establish relative contributions nonfounder mutations, we established entire spectrum BRCA2 a large set families with origins regions...
Abstract The known breast cancer susceptibility polymorphisms in FGFR2, TNRC9/TOX3, MAP3K1, LSP1, and 2q35 confer increased risks of for BRCA1 or BRCA2 mutation carriers. We evaluated the associations 3 additional single nucleotide (SNPs), rs4973768 SLC4A7/NEK10, rs6504950 STXBP4/COX11, rs10941679 at 5p12, reanalyzed previous using carriers a sample 12,525 7,409 Additionally, we investigated potential interactions between SNPs assessed implications risk prediction. minor alleles were...
Prophylactic bilateral salpingo-oophorectomy is recommended for BRCA1 mutation carriers to prevent ovarian cancer. Whether or not hormone replacement therapy (HRT) initiated after oophorectomy associated with an increased risk of breast cancer has been evaluated in a prospective study.To determine the association between HRT use and BRCA1-associated cancer.A prospective, longitudinal cohort study BRCA2 from 80 participating centers 17 countries was conducted 1995 2017 mean follow-up 7.6...
To estimate 10-year overall survival (OS) rates for patients with early-onset breast cancer, and without a BRCA1 mutation, to identify prognostic factors among those BRCA1-positive cancer.A total of 3,345 women stage I III age ≤ 50 years, were tested three founder mutations in BRCA1. Information on tumor characteristics treatments received was retrieved from medical records. Dates death obtained the vital statistics registry. Survival curves mutation-positive -negative subcohorts compared....